Ikena Oncology, Inc. (IKNA)
NASDAQ: IKNA · IEX Real-Time Price · USD
1.270
-0.010 (-0.78%)
At close: Apr 16, 2024, 4:00 PM
1.340
+0.070 (5.51%)
After-hours: Apr 16, 2024, 6:21 PM EDT

Ikena Oncology Statistics

Total Valuation

Ikena Oncology has a market cap or net worth of $61.29 million. The enterprise value is -$103.44 million.

Market Cap 61.29M
Enterprise Value -103.44M

Important Dates

The next estimated earnings date is Monday, May 13, 2024, before market open.

Earnings Date May 13, 2024
Ex-Dividend Date n/a

Share Statistics

Ikena Oncology has 48.26 million shares outstanding. The number of shares has increased by 15.33% in one year.

Shares Outstanding 48.26M
Shares Change (YoY) +15.33%
Shares Change (QoQ) +10.21%
Owned by Insiders (%) 7.00%
Owned by Institutions (%) 100.01%
Float 17.90M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 6.69
Forward PS 7.36
PB Ratio 0.36
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 12.58, with a Debt / Equity ratio of 0.06.

Current Ratio 12.58
Quick Ratio n/a
Debt / Equity 0.06
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -44.20% and return on invested capital (ROIC) is -41.78%.

Return on Equity (ROE) -44.20%
Return on Assets (ROA) -37.30%
Return on Capital (ROIC) -41.78%
Revenue Per Employee $213,023
Profits Per Employee -$1.59M
Employee Count 43
Asset Turnover 0.05
Inventory Turnover n/a

Taxes

Income Tax -162,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -73.50% in the last 52 weeks. The beta is 0.33, so Ikena Oncology's price volatility has been lower than the market average.

Beta (1Y) 0.33
52-Week Price Change -73.50%
50-Day Moving Average 1.41
200-Day Moving Average 3.01
Relative Strength Index (RSI) 44.75
Average Volume (30 Days) 427,851

Short Selling Information

The latest short interest is 1.25 million, so 2.59% of the outstanding shares have been sold short.

Short Interest 1.25M
Short Previous Month 1.12M
Short % of Shares Out 2.59%
Short % of Float 6.99%
Short Ratio (days to cover) 3.19

Income Statement

In the last 12 months, Ikena Oncology had revenue of $9.16 million and -$68.17 million in losses. Loss per share was -$1.63.

Revenue 9.16M
Gross Profit 9.16M
Operating Income -75.42M
Pretax Income -68.33M
Net Income -68.17M
EBITDA -65.59M
EBIT -68.33M
Loss Per Share -$1.63
Full Income Statement

Balance Sheet

The company has $175.47 million in cash and $10.74 million in debt, giving a net cash position of $164.73 million or $3.41 per share.

Cash & Cash Equivalents 175.47M
Total Debt 10.74M
Net Cash 164.73M
Net Cash Per Share $3.41
Equity / Book Value 169.76M
Book Value Per Share 3.52
Working Capital 164.46M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$79.74 million and capital expenditures -$414,000, giving a free cash flow of -$80.16 million.

Operating Cash Flow -79.74M
Capital Expenditures -414,000
Free Cash Flow -80.16M
FCF Per Share -$1.92
Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -823.33% and -744.17%.

Gross Margin 100.00%
Operating Margin -823.33%
Pretax Margin -745.94%
Profit Margin -744.17%
EBITDA Margin -716.09%
EBIT Margin -745.94%
FCF Margin -875.08%

Dividends & Yields

Ikena Oncology does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -15.33%
Shareholder Yield -15.33%
Earnings Yield -111.22%
FCF Yield -130.79%

Analyst Forecast

The average price target for Ikena Oncology is $10.67, which is 740.16% higher than the current price. The consensus rating is "Strong Buy".

Price Target $10.67
Price Target Difference 740.16%
Analyst Consensus Strong Buy
Analyst Count 3
Revenue Growth Forecast (5Y) 54.12%
EPS Growth Forecast (5Y) -13.70%
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Ikena Oncology has an Altman Z-Score of -0.51 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -0.51
Piotroski F-Score 1